Xeris Biopharma Holdings, Inc. 4

CFO Steven Pieper sold a total of 45,000 shares of Xeris Biopharma Holdings, Inc. common stock for roughly $383,000 under a Rule 10b5-1 plan.

On July 6 and 7, 2026, Xeris Biopharma Holdings, Inc. Chief Financial Officer Steven Pieper sold a total of 45,000 shares of the company’s common stock under a pre-established Rule 10b5-1 trading plan. He sold 17,400 shares on July 6 at $8.50 per share for proceeds of approximately $147,900, followed by a sale of 27,600 shares on July 7 at a weighted average price of $8.5245 per share for proceeds of approximately $235,265. After these planned sales, which were executed at prices between $8.50 and $8.60 per share, Pieper reported direct ownership of 1,366,053 shares, which, using the recent sale prices as a proxy, represents a holding value of roughly $11.6–$11.7 million. The filing also notes that his holdings include 2,113 shares acquired on June 30, 2026 under the company’s Employee Stock Purchase Plan.

Filing Facts

CIK

1867096

Ticker

XERS

Form

4

Source Type

sec

Accession

0001875714-26-000007

Alert Tier

6